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PAntiplatelet Therapy
atching the Evaluation of the Clinical
fficacy of Clopidogrel to Platelet Function Tests
elevant to the Biological Properties of the Drug
enoît Labarthe, PHARMD,* Pierre Théroux, MD, FACC,* Michaël Angioï, MD, PHD,† Marta Ghitescu*
ontreal, Canada; and Nancy, France
OBJECTIVES This study aimed to explore platelet function tests relevant to the biological effects of
clopidogrel that could help the clinical monitoring of drug efficacy.
BACKGROUND Clopidogrel selectively inhibits the P2Y12 receptor, the major role of which is stabilization of
aggregation, whereas initiation of aggregation depends on activity of both P2Y1 and P2Y12
receptors.
METHODS Tests used were peak aggregation (Aggmax) and late aggregation (Agg6min), and disaggrega-
tion, relating to P2Y1 and P2Y12 activity, respectively; and monoclonal antibody binding
activated glycoprotein (GP) IIb/IIIa receptors (PAC-1) and P-selectin, measuring activation
and secretion. A first study compared hirudin/PPACK (r-hirudin and D-phenylalanyl-prolyl-
arginine chloromethyl ketone) with citrate as blood anticoagulant (16 patients), and a second
control study compared the effects of clopidogrel, aspirin, or both (20 normal controls).
RESULTS Clopidogrel similarly inhibited adenosine 5=-diphosphate (ADP)-induced Aggmax with either
anticoagulant, but significantly more Agg6min (75% vs. 31%), P-selectin (72% vs. 53%), and
PAC-1 (62% vs. 24%) in hirudin/PPACK. In the control study, it inhibited Aggmax by 22%,
and Agg6min, P-selectin, and PAC-1, by 69%, 66%, and 55%, respectively (all p  0.05).
Disaggregation at six min reached 62% with clopidogrel, but was virtually absent with placebo
and aspirin. Non-responsiveness as evaluated by inhibition of Aggmax in citrate was diagnosed
in 35% of patients; in half this rate by Agg6min, P-selectin, and PAC-1; and in 6% to 12%
with the latter tests performed in hirudin/PPACK.
CONCLUSIONS The evaluation of clopidogrel responsiveness by platelet function tests is largely influenced by
the choice of blood preservative and functional tests. Measures of aggregation stabilization,
and of consequent secretion and activation, identified most patients as responders, contrasting
with measures of peak aggregation, by likely reflecting better the interactions clopidogrel and
the P2Y12 receptor. (J Am Coll Cardiol 2005;46:638–45) © 2005 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.092of Cardiology Foundation
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clopidogrel is a thienopyridine that specifically inhibits the
urinergic P2Y12 receptors. The drug is recommended as
lternative therapy to aspirin in the secondary prevention of
ardiovascular events and in combination with aspirin for
atients with an acute coronary syndrome or undergoing
tent implantation. It is currently investigated as adjunct
herapy to fibrinolysis in acute myocardial infarction and in
See page 646
he prevention of thromboembolic events in high-risk pa-
ients. Despite its growing use, a high degree of inter-
ndividual variability is described in response to clopidogrel,
ith non-response in a substantial number of patients (1–3).
onsidering the potentially serious consequences of such
oor response, many have expressed a need for a platelet
From the *Department of Medicine, Montreal Heart Institute and University of
ontreal, Montreal, Quebec, Canada, and the †Département de Cardiologie,
ôpitaux de Brabois, Centre Hospitalier Universitaire de Nancy, Nancy, France.d
Manuscript received November 15, 2004; revised manuscript received February 3,
005, accepted February 8, 2005.unction tests that could permit reliable evaluation of
linical efficacy (4). This need is reinforced by the results of
few small studies that described a higher risk of events in
atients whose condition responded poorly (5–7). These
esults, however, and the risk gradient associated with a
oor response, remain to be validated in larger datasets and
rospective studies. Most studies to date have defined
lopidogrel resistance as an inadequate inhibition of peak
denosine 5=-diphosphate (ADP)-induced ex vivo platelet
ggregation in blood sampled in sodium citrate (2,5,6,8,9).
hese methods, although measuring the activity of platelet
urinergic receptors, may have drawbacks because clopi-
ogrel, and other thienopyridines as well, blocks the puri-
ergic P2Y12 receptor but not the P2Y1 receptor; the former
s mainly involved in stabilization of aggregates (10), and
he latter in initiation of platelet shape changes and of
latelet aggregation. On the other hand, although ADP is
onsidered a weak platelet agonist, a number of direct or
ndirect pharmacodynamic effects have been described with
lopidogrel that could be useful to the clinical monitoring of
rug responsiveness (11,12).
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August 16, 2005:638–45 Evaluation of Clopidogrel ResponsivenessThis study explored issues related to the ex vivo evalua-
ion of clopidogrel efficacy and various platelet function tests
ith the goal of identifying a test that could eventually be
linically useful. Tests related to platelet aggregation, acti-
ation, secretion, and disaggregation after initial aggrega-
ion, the latter reflecting better the activity of the P2Y12
eceptor than that of the P2Y1 receptor, were compared in
lood preserved with either citrate or antithrombins.
ETHODS
tudy populations and designs. Two separate studies were
erformed after being approved by the Montreal Heart
nstitute Internal Ethics Committee and were carried out in
ompliance with the Declaration of Helsinki’s recommen-
ations. All participants signed an informed consent form
efore inclusion. Individuals with a contraindication to
ntiplatelet therapy or using a drug other than aspirin that
nterferes with platelet function or coagulation were
xcluded.
The first study was designed to characterize the influence
n platelet function tests of using antithrombins as an
nticoagulant in place of sodium citrate. This study was
pen labeled and included 16 patients with stable angina
lready using aspirin 80 mg daily and scheduled for an
ngioplasty on an outpatient basis. Clopidogrel at a daily
aintenance dose of 75 mg was initiated seven days before
he planned procedure. The first blood sample was obtained
mmediately before the initiation of clopidogrel, and the
econd before the angioplasty procedure.
The goal of the second study was to describe the effects of
lopidogrel on different platelet function tests; a random-
zed, double-blind, placebo-controlled design was used. The
tudy included 20 patients partitioned in one of three
arallel groups (Fig. 1). Blood samplings were obtained 24 h
part in a fasting state on three consecutive days. The
esearch nurse administered the study drugs immediately
fter the baseline sampling on day 1, and after the second
ampling on day 2. The loading dose of clopidogrel was 300
g and the maintenance dose was 75 mg, and those of
spirin were 300 mg and 80 mg, respectively. Subjects in the
rst group received the loading dose of clopidogrel and
Abbreviations and Acronyms
ADP  adenosine 5=-diphosphate
Agg6min  late aggregation
Aggmax  peak aggregation
ASA  acetylsalicylic acid
GP  glycoprotein
hirudin/PPACK  r-hirudin and D-phenylalanyl-
prolyl-arginine chloromethyl ketone
PAC-1  monoclonal antibody binding
activated glycoprotein IIb/IIIa
receptors
TRAP  thrombin receptor agonist peptidelacebo-aspirin on the first day, and a maintenance dose of
F
plopidogrel and the loading dose of aspirin on the second
ay. In the second group, they received on day 1 placebo-
lopidogrel and the loading dose of aspirin, and on day 2 the
oading dose of clopidogrel and the maintenance dose of
spirin. In the third group, placebo-clopidogrel and
lacebo-aspirin were used on both the day 1 and day 2
Fig. 1).
latelet aggregation studies. For the first study, blood was
ollected from a forearm vein and withdrawn into two tubes,
ne containing sodium citrate 3.8% (Becton Dickinson,
ississauga, Ontario), and the second containing hirudin 2
/ml and D-phenylalanyl-prolyl-arginine chloromethyl ke-
one (PPACK) 40 mol/l (Calbiochem, La Jolla, California).
ased on results from the first study, only the hirudin/
PACK tube was used in the second randomized study.
The same instrumentation and methodology was other-
ise used for the two studies, except for different concen-
rations of the two agonists used. In the first study, ADP
nd a thrombin receptor activating peptide-6 (TRAP-6,
igma Chemical Co., Oakville, Ontario, Canada) were used
ach at a higher concentration of 10 mol/l to better
ifferentiate the effects of citrate and of the antithrombins;
n the second study, the agonists were used at lower
oncentrations of 2.5 mol/l to more selectively study the
ffects of ADP on dependent receptors and pathways.
Platelet aggregation was measured by light transmission
model 570VS with AggroLink software package, Chro-
olog Corp., Havertown, Pennsylvania) in stirred (1,000
pm) platelet-rich plasma (PRP). The platelet-rich plasma
as prepared by the centrifugation from whole blood at 130
for 10 min and platelet-poor plasma by the centrifugation
f the remaining blood at 1,800 g for 15 min. The platelet
ount was adjusted to 250,000 platelets/l with platelet-
oor plasma; platelet-rich plasma and platelet-poor plasma
ere used to set the light transmission to 0% and 100%,
espectively. Aggregation was measured at peak (Aggmax),
hich is seen approximately 1 min after the addition of the
gonists, and at the end of the test after 6 min (Agg6min).
nhibition of aggregation was calculated as the percent
ecrease in aggregation values obtained at baseline and on
reatment. A percentage of disaggregation (D) between
ggmax values and Agg6min was calculated as: D (%) 
00 · (1  Agg6min/Aggmax). Figure 2 illustrates a series ofigure 1. Design of the double-blind placebo-controlled randomized study
erformed in normal volunteers (Study 2).
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Evaluation of Clopidogrel Responsiveness August 16, 2005:638–45ggregation curves obtained on three different days in one
ormal individual from Group 1 of the randomized study.
latelet secretion and activation. Platelet membrane ex-
ression of P-selectin, secreted from the -granules, and of
onoclonal antibody binding activated glycoprotein (GP)
Ib/IIIa receptors (PAC-1), a monoclonal antibody that
electively binds the GP IIb/IIIa receptor when activated,
as quantified in whole blood by flow cytometry. They serve
s measures of platelet secretion and activation, respectively.
he hirudin/PPACK blood was diluted in a 1:5 ratio within
5 min of being drawn with a modified Tyrode buffer
olution (TBS) (containing NaCl, 137 mM; KCl, 2.8 mM;
gCl2, 6H2O, 1 mM; NaHCO3, 12 mM; Na2HPO4, 0.4
M; bovine serum albumin, 0.35%; HEPES, 10 mM; and
lucose, 5.5 mM; pH, 7.4); 13 l diluted blood was divided
nd poured into Eppendorf tubes containing saturating
oncentrations of antibodies and 12 l ADP 100 M
Sigma Chemical Co.) dissolved in Tyrode buffer solution
o a final concentration of 10 M. The samples were
ncubated with the antibodies without stirring for 30 min at
oom temperature, and adding 500 l of formaldehyde 1%
topped further reaction. The antibodies used were PAC-1,
fluorescein isothiocyanate-conjugated immunoglobulin M
olyclonal antibody that specifically binds the activated GP
Ib/IIIa receptors, and anti-CD 62P, a phycoerythrine-
igure 2. Aggregation curves from a normal individual, obtained after the
gonist peptide (TRAP) 2.5 M in platelet-rich plasma at baseline (left);
f clopidogrel 75 mg and aspirin (ASA) 300 mg (right). Disintegration is m
nd significant in the presence of TRAP. Aspirin added no additional disonjugated murine monoclonal antibody immunoglobulin s1 directed against platelet membrane P-selectin (Becton
ickinson, San Jose, California). Flow cytometer readings
ere done within one h of blood sampling on a total of
,000 platelets per sample. Forward scatter identified the
latelet population for cell size and side scatter for cell
ranularity. The percentage of fluorescence-positive plate-
ets was obtained in duplicate from the instrument computer
ystem (Beckman Coulter Epics XL, Miami, Florida).
tatistical analysis. Because most data were non-normally
istributed, non-parametric methods were used and data are
xpressed as median and interquartile range; 5th and 95th
ercentiles are also shown in the figures. Statistical analyses
ere performed with the SPSS 10.0 for Windows statistical
oftware (SPSS Inc., Chicago, Illinois). Paired comparisons
f aggregation, and P-selectin and PAC-1 expression values
ere done with the Wilcoxon paired test, and unpaired
omparisons were done with the Mann-Whitney and
ruskal-Wallis tests. Correlations were evaluated using
pearman non-parametric rho coefficients. The response to
lopidogrel was assessed using chi-square tests by referring
o the criteria published by Lau et al. (8), i.e.,10% relative
nhibition being non-response; 10% to 30%, poor response,
nd 30%, good response. These criteria were also applied
o quantify P-selectin and PAC-1 expression. The level of
tion of adenosine 5=-diphosphate (ADP) 2.5 M and thrombin receptor
after a loading dose of clopidogrel (middle); and 24 h later, after a dose
al at baseline and nearly complete after clopidogrel in the presence of ADP
ation.addi
24 hignificance for two-sided hypothesis tests was set at a p
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August 16, 2005:638–45 Evaluation of Clopidogrel Responsivenessalue 0.05; no correction factors were introduced for
ultiple analyses.
ESULTS
tudy populations and platelet parameters. Sixteen pa-
ients (1 woman, 15 men; median age, 70 years; range, 59 to
5 years) were enrolled in the first study, and 20 normal
olunteers (9 women, 11 men; median age, 42 years; range,
6 to 46 years) in the randomized study. No significant
ifferences in clinical characteristics emerged between the
hree groups in the latter study. Basal whole blood platelet
ounts were similar in patients and controls, as were counts
n the serial samples obtained throughout the course of the
wo studies. Results of platelet function tests were in general
ittle influenced by the concentration of 10 M used in the
rst study and of 2.5 M in the second study: peak
ggregations were 65% and 70%; percent inhibitions by
lopidogrel were 31% and 22%; PAC-1 binding, 62% and
5%; P-selectin expression, 42% and 42%; and disaggrega-
ion rates, 4% and 1.4%. No controls and no patients
howed a second aggregation wave.
The responses to ADP and TRAP at baseline were also
he same in the three parallel groups of the randomized
tudy, and were highly reproducible on the three consecutive
ays’ sample among individuals who were only administered
he placebo.
nfluence of hirudin/PPACK and of citrate. In the basal
tate, the usage of either hirudin/PPACK or citrate as a
lood preservative did not significantly influence measures
f the agonist effects of ADP and of TRAP on aggregation
nd disaggregation rates and on P-selectin expression.
igure 3. Inhibition of platelet functions in platelet-rich plasma prepared
rginine chloromethyl ketone (hirudin/PPACK) (boxes with vertical lines)
d) glycoprotein (GP) IIb/IIIa activation by monoclonal antibody binding a
ither a thrombin receptor activating peptide-6 (left panels) or adenosine 5=dip
he interquartile range, whiskers are the 5th and 95th percentiles, and p valuesowever, PAC-1 binding was reduced in response to ADP
p  NS) and to TRAP (p  0.01) in hirudin/PPACK.
With clopidogrel, the inhibition of peak aggregation was
imilar in antithrombins and in citrate, but the inhibition of
ate aggregation, P-selectin expression, and PAC-1 binding
n response to ADP was significantly higher in antithrom-
ins. Figure 3 illustrates the distribution of the individual
ata points. Thus, a modest 20% inhibition (6% to 38%)
n peak ADP-induced aggregation was observed in citrate,
hereas an important 75% (54% to 94%) inhibition of late
ggregation occurred in hirudin/PPACK plasma. Similarly,
he inhibition of TRAP- induced late aggregation and
AC-1 binding was slightly although non-significantly
reater in hirudin/PPACK than in citrate (Fig. 3). More-
ver, although no difference was measured at baseline (1%
s. 4%; p  0.6), disaggregation of ADP-aggregated plate-
ets by clopidogrel was greatly enhanced in analyses per-
ormed in hirudin/PPACK compared with citrate (66% vs.
9%; p  0.001).
ffects of aspirin in healthy donors (randomized study).
spirin administered alone or with clopidogrel had no
etectable effects on peak and late aggregation to ADP and
RAP-6. Aspirin increased ADP- and TRAP-induced
-selectin expression by 3% (p  0.03) and 5% (p  0.04),
espectively, and TRAP-induced PAC-1 binding by 8% (p
0.01). These activations, however, were prevented with
he pre-administration of clopidogrel.
ffects of clopidogrel. Clopidogrel inhibited ADP-
nduced peak aggregation by a median of 22% (p  0.01)
nd TRAP-induced aggregation by 7% (NS). By contrast,
s seen in Table 1, late aggregations to ADP and TRAP
ere markedly more reduced with clopidogrel by 69% (p 
odium citrate (open boxes) versus r-hirudin and D-phenylalanyl-prolyl-
0.05). (a) Peak aggregation, (b) late aggregation, (c) P-selectin expression,
ted GP IIb/IIIa receptors (PAC-1) measure after agonist stimulation within s
(*p
ctivahosphate (ADP) (right panels). Horizontal lines are medians, boxes are
were obtained using the Wilcoxon signed-rank test; *p  0.05.
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Evaluation of Clopidogrel Responsiveness August 16, 2005:638–45.001) and 29% (p 0.001), respectively, because of rates of
isaggregation from peak to 6 min of 62% (36% to 98%;
 0.01) for ADP and of 11% (10% to 41%; p  0.01) for
RAP. Disaggregation was virtually absent with the pla-
ebo, 1% (0% to 9%; p  0.7) and 0% (0% to 1%; p  0.3)
espectively, and with aspirin, 2% (0% to 9%; p  0.5) and
% (0% to 8%; p 0.6). Figure 2 illustrates the aggregation
urves of a representative case, and Figure 4 shows the data
n each normal individual.
The P-selectin expression with ADP and TRAP was
educed by 66% (p  0.01) and 22% (p  0.04), respec-
ively, and PAC-1 binding by 55% (p  0.001) and 54%
p  0.001). The magnitudes of all of these inhibition rates
ere similar regardless of whether aspirin was administered
fter (Group 1) or before (Group 2) clopidogrel (Table 1).
While on clopidogrel, strong correlations existed between
nhibition of aggregation at 6 min and both P-selectin
xpression (r  0.7, p  0.001) and PAC binding (r  0.6,
 0.02), and also between the latter two (r  0.8, p 
.001).
lopidogrel resistance. The application of the conven-
ional criteria of responsiveness to clopidogrel based on
nhibition of peak aggregation measured in platelet-rich
lasma prepared in citrate divided our population of stable
atients into approximately one-third responders, one-third
oor responders, and one-third non-responders (Table 2).
hen peak aggregation was measured in blood with the
ntithrombins, twice as many patients were responders and
hree times fewer patients were non-responders. Similar
hifts in distribution were observed, on the one hand, with
ate aggregation, P-selectin, and PAC-1 measured in hirudin/
PACK compared with citrate, and on the other hand, in
ate aggregation compared with peak aggregation, both
eing measured in hirudin/PPACK. Thus, measurements
f late aggregation, P-selectin, and PAC-1 in hirudin/
PACK identified 94%, 82%, and 77% of patients respec-
ively as responders, and 6%, 6%, and 12% as non-
esponders. Furthermore, the demarcation between
esponders and non-responders was also more clearly delin-
ated, with fewer patients being borderline poor responders
Table 2).
Similar response rates were observed in the randomized
tudy of normal volunteers in which only hirudin/PPACK
as used as an anticoagulant. With the loading dose of 300
g clopidogrel, measures of peak aggregation, late aggre-
ation, P-selectin, and PAC-1 resulted in non-response
ates of 25%, 6%, 0% and 6%, respectively.
ISCUSSION
his study shows high degrees of inter-individual variability
n the response to clopidogrel and high rates of non-
esponse, comparable with those reported in the literature,
hen using the conventional approach of measuring inhi-bition of ADP-induced peak aggregation in citratedTa
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August 16, 2005:638–45 Evaluation of Clopidogrel Responsivenesslatelet-rich plasma. Based on such results, a concept of
lopidogrel resistance was elaborated (2,5,13,14). Our re-
ults, however, challenge the significance of such a concept
ased on a simple test of aggregation that is influenced by
ctivity of both the P2Y1 and P2Y12 purinergic receptors,
hereas clopidogrel blocks only the latter. Indeed, a much
ower rate of variability was found by looking at stabilization
f aggregation, measured by disaggregation and late aggre-
ation, which is mainly driven by the activity of P2Y12
eceptor, and at markers of platelet secretion and activation.
he variability was further reduced when these tests were
erformed in blood preserved with antithrombins rather
han citrate. Combining these approaches, the non-
esponse rate was reduced from 35% to 6%.
irudin/PPACK versus sodium citrate. Contrasting
ith other antiplatelet drugs, no studies to our knowledge
ave directly compared the use of an antithrombin versus
itrate in measuring the effects of clopidogrel (15). Hirudin/
PACK in this study provided better detection of the
nhibitory effects of clopidogrel on disaggregation, late
ggregation, P-selectin expression, and GP IIb/IIIa activa-
ion. Interestingly peak aggregation measures were not
nfluenced by the selection of the preservative. Although
igure 4. Percent disaggregation from peak aggregation to six min after
gonist peptide (TRAP) (bottom) in healthy volunteers, at baseline on D
rug administration on Day 3. Open boxes are either at baseline or after
re after clopidogrel (doses shown in Fig. 1, and an actual tracing in Fig
hiskers are the 5th and 95th percentiles, and p values were obtained by
Table 2. Responsiveness to Clopidogrel by Bloo
Sodium Citrate
Aggmax Agg6min PA
Good response (%) 29 59 4
Low response (%) 35 24 3
Non-response (%) 35 18 2Study performed in patients with stable coronary artery disease. Se
Hirudin/PPACK  r-hirudin and D-phenylalanyl-prolyl-arginidely used as an anticoagulant when studying ex vivo
latelet functions, sodium citrate possesses shortcomings
ecause it promotes P-selectin expression (16) and micro-
ggregate formation likely in relation with platelet activa-
ion signaled by the binding of fibrinogen to GP IIb/IIIa
eceptors (17,18).
ffects of ASA. Aspirin had no detectable effect on the
ests used in this study regardless of the presence of
lopidogrel, consistent with published data that described
o effects of aspirin on ADP-induced aggregation (19–21),
D62P, CD63, and PAC-1 expression, and platelet-
eukocytes conjugate formation (11). On the other hand,
cetylsalicylic acid (ASA) can potentiate the effects of
lopidogrel on less specific function tests such as bleeding
ime (22) and aggregation induced by type 1 collagen or
RAP 15 M (19). The ASA also inhibits the second
hase of ADP-induced aggregation by preventing throm-
oxane A2 production. No second wave of aggregation was
een in this study because the 10-M concentration was
sed in patients pretreated with ASA, and the sub-
hreshold concentration of 2.5 M was used in controls. In
he two instances, however, clopidogrel clearly prevented
ustained aggregation because it consistently promoted dis-
dition of adenosine 5=-diphosphate (ADP) (top) and thrombin receptor
24 h after the first drug administration on Day 2, and 24 h after the last
bo, boxes with diagonal lines are after aspirin, boxes with vertical lines
The horizontal lines are medians, the boxes are the interquartile range,
ilcoxon signed-rank test; *p  0.05.
servative and Tests of Platelet Function Used
Hirudin/PPACK
Psel Aggmax Agg6min PAC Psel
75 53 94 77 82
12.5 35 0 11 12
12.5 12 6 12 6the ad
ay 1,
placed Pre
C
1
0
9e text for definition of good, low, and non-response.
ine chloromethyl ketone; other abbreviations as in Table 1.
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Evaluation of Clopidogrel Responsiveness August 16, 2005:638–45ggregation. The TRAP effects were not influenced by
SA, as previously documented (20,23).
ffects of clopidogrel. Clopidogrel produced a profound
nd predictable inhibition of late aggregation in relation to
apid disaggregation of emerging aggregates, contrasting
ith the modest and variable inhibition of peak aggregation
bserved in this and other studies (1,2,6,14). Only one
revious study reported on late aggregation, and did not
efer to variability in response (21).
The TRAP data extend to disaggregation our previous
bservation on the inhibitory effects of clopidogrel on peak
ggregation, P-selectin, PAC-1, and platelet-monocyte
onjugates formation (12). Although less pronounced than
or ADP, the disaggregation after TRAP was of greater
agnitude than the inhibition of Aggmax. These data are
onsistent with the known influence of purinergic receptors
n the activity of protease activated receptor-1 (24). The
hysiologic importance of the observations may be debat-
ble because TRAP may release calcium through mecha-
isms different than that of thrombin that involve protease
ctivated receptor-4 delayed signaling (24,25). The inhibi-
ions of PAC-1 and on P-selectin by clopidogrel were
redictable because they relate to ADP agonists’ effects on
latelet activation.
esistance to clopidogrel. Previously reported prevalence
ates of clopidogrel resistance, measured as absolute differ-
nce to baseline aggregation, were within the range of 24%
o 40% (1,2,9,26). Using more restrictive definitions of
10% relative inhibition, Muller et al. (6) and Lau et al. (8)
ould reduce these rates to 5% and 22% of patients,
espectively. The non-response rates of 35% observed
hrough using peak aggregation in this study could be
educed to 12% when the analyses were performed in
irudin/PPACK blood rather than in citrate, and further
own to 6% when late aggregation was studied instead of
eak aggregation. Disaggregation was always present with
lopidogrel and absent without clopidogrel. Similar low
on-response rates of 6% were seen with both P-selectin
xpression and PAC-1 binding when assessed in hirudin/
PACK, compared with rates of 12.5% and 29%, respec-
ively, in sodium citrate.
tudy limitations and clinical implications. The low
on-response rates observed herein are unlikely related to
he concentrations of agonists (4) because they were ob-
erved at both low and high concentrations of ADP and of
RAP, and at concentrations similar to that used in most
tudies that showed these high rates. Although other factors
elated to individuals studied or to methodologic aspects
ould have influenced the results, they were unlikely of
mportance because results were consistent in two different
opulations, with two different agonists, two different con-
entrations of ADP, and different tests of platelet function
xamining platelet secretion, activation, and aggregation
nd disaggregation.
Although reproducible, the findings of this study are not
direct documentation of clinical relevance. For this pur-ose, large clinical trials matching clinical efficacy to bio-
ogical effects will be required.
Nonetheless, the results of the study, along with the
onclusive efficacy data derived from clinical trials and the
nown selective blocking effect of clopidogrel on the P2Y12,
trongly support a measure of late aggregation or disaggre-
ation as a more appropriate assay to measure clopidogrel
fficacy than aggregation. These mechanistic and conceptual
ssues are relevant to the evaluation of clopidogrel efficacy
nd carry implications for patients’ treatment for and
evelopment of new generations of ADP receptor blockers.
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